Quantcast

Latest Herceptin Stories

2008-06-14 03:00:00

By Hicks, David G Kulkarni, Swati * Context.-Overexpression of human epidermal growth factor receptor 2 (HER2) is an adverse prognostic parameter for patients with breast cancer. Patients with HER2- positive tumors are, however, likely to gain significant benefit from targeted therapy with trastuzumab. Four largescale trials have assessed the efficacy and safety of adjuvant trastuzumab. In all 4 trials, disease-free survival and overall survival were significantly improved with adjuvant...

2006-08-22 18:03:21

LONDON (Reuters) - Britain's cost-effectiveness watchdog issued final guidance on Wednesday recommending that Herceptin should be used in early breast cancer and be paid for by the state health service. The move by the National Institute of Health and Clinical Excellence (NICE) clears the way for the drug to be prescribed on the National Health Service for women with aggressive HER2 breast cancer following surgery. NICE had given a preliminary green light to the Roche medicine in...

2006-07-20 11:40:14

By Ben Hirschler, European Pharmaceuticals Correspondent LONDON (Reuters) - Recent advances in treatment mean it is possible to start talking about curing some types of cancer, the world's biggest maker of cancer drugs said on Thursday. Swiss-based Roche argued the use of modern medicines, such as breast cancer drug Herceptin, at an early stage of disease was transforming the outlook for patients. "There is a quantum leap here," William Burns, Roche's head of pharmaceuticals, told...

2006-06-03 14:18:49

By Lisa Richwine ATLANTA (Reuters) - An experimental drug added to chemotherapy slowed aggressive, late-stage breast cancers that resumed growing despite standard treatment with the drug Herceptin, U.S. researchers said on Saturday. The drug, Tykerb, by GlaxoSmithKline Plc, also showed potential to help some patients with advanced kidney cancer, another study showed. Glaxo hopes to begin selling the drug next year, but must await regulatory approval. Industry analysts predict it...

2006-05-29 07:42:21

ZURICH (Reuters) - Roche on Monday unveiled new data showing that its cancer drug Herceptin increased the time that some breast-cancer patients live without the cancer progressing when used in combination with hormonal therapy. The Swiss pharmaceutical group Roche said the late-stage, or Phase III, trial results were for patients whose advanced breast cancer was hormone receptor-positive, as well as HER2-positive, a particularly aggressive form of the disease. Hormone...

2006-05-29 01:44:16

ZURICH (Reuters) - Roche on Monday unveiled new data showing that its cancer drug Herceptin increased the time that some breast-cancer patients live without the cancer progressing when used in combination with hormonal therapy. The Swiss pharmaceutical group Roche said the late-stage, or Phase III, trial results were for patients whose advanced breast cancer was hormone receptor-positive, as well as HER2-positive, a particularly aggressive form of the disease. Hormone...

2006-05-24 08:40:07

ZURICH (Reuters) - Swiss drug maker Roche said on Wednesday the European Union had approved its Herceptin cancer drug for use in patients in an early stage of the aggressive HER2-positive type of breast cancer. "The approval is based on... (a) study which showed Herceptin following standard chemotherapy significantly reduces the risk of cancer coming back by 46 percent compared to chemotherapy alone," Roche said in a statement. Herceptin was previously approved in the EU for...

2006-05-08 14:36:13

LONDON (Reuters) - A 37-year-old man with breast cancer was told on Monday his local NHS trust will fund treatment with the potentially life-saving drug Herceptin, a move that will add to the debate about its use and funding. Maidstone Weald Primary Care Trust said it had agreed to fund the treatment after considering Stuart Weaver's clinical needs and advice from his medical consultants. "We have just spoken with Mr Weaver and he was happy with the news," the trust said in a...

2006-04-12 05:30:00

By Michael Holden LONDON -- A British woman with early-stage breast cancer won a legal appeal on Wednesday to force her local health authority to pay for the potentially life-saving drug Herceptin. "I feel like I've won the lottery," said Ann Marie Rogers, 54, who had called the initial decision by Swindon Primary Care Trust (PCT) not to give her the costly medication "a death sentence." The decision at London's Court of Appeal overturned an earlier High Court ruling that said the PCT in...

2006-03-27 08:10:00

LONDON (Reuters) - A British woman with early-stage breast cancer went to the Court of Appeal in London on Monday in a bid to force her health authority to pay for the potentially life-saving drug Herceptin. Ann Marie Rogers, 54, is appealing against a High Court ruling last month that Swindon Primary Care Trust in Wiltshire need not pay for the costly medication, made by Switzerland's Roche. At an earlier hearing, the judge was told that Rogers felt as though she had been given "a death...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related